Characterization of Former Gestational Diabetes Mellitus: Prognostic, Therapeutic, and Predictive Aspects
1Metabolic Unit, ISIB-CNR, 35127 Padova, Italy
2Unit of Gender Medicine, Division of Endocrinology and Metabolism, Clinic of Internal Medicine III, Medical University of Vienna, Vienna, Austria
3Department of Endocrinology and Metabolism, University of Pisa; Ospedale di Livorno, Azienda USL 6 Livorno, Livorno, Italy
4Department of Obstetrics, Helen Schneider Hospital for Women, Rabin Medical Center, Beilinson Campus, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Characterization of Former Gestational Diabetes Mellitus: Prognostic, Therapeutic, and Predictive Aspects
Description
Women with previous gestational diabetes mellitus (pGDM) are at risk for the later development of type 2 diabetes. High glycemic levels during pregnancy or after delivery probably remain the strongest predictors for diabetes development in women with pGDM. However, the risk is increased when the condition of pGDM is accompanied by other factors that predispose to diabetes also in different categories of subjects, like improper diet habits, sedentary lifestyle, obesity, or weight gain. Besides, it is not completely clear whether the history of gestational diabetes itself can be an independent risk factor for future diabetes. As a matter of fact, though there are several studies that included pGDM women, analysis of the results is often poor or only performed retrospectively (post hoc analysis).
Authors are invited to submit original research and review articles regarding the pathophysiology of glucose and lipid metabolism in women with pGDM and the identification of early markers for the risk of developing type 2 diabetes and related cardiovascular complications. Trials on possible therapeutic strategies based on early pharmacological intervention are also of interest. Reports on educational programs for behavior modification and improved awareness in pGDM women will also be considered. Potential topics include, but are not limited to:
- pGDM and preconception conditions and/or diseases
- pGDM and conditions and/or diseases during pregnancy
- pGDM and metabolic syndrome
- pGDM and ethnicity
- pGDM and lifestyle (nutrition and exercise)
- Markers of insulin sensitivity and beta-cell function in pGDM
- Characterization of the risk of overt type 2 diabetes in pGDM
- Micro- and macrovascular complications in pGDM
- Gynecological aspects of pGDM
- Immunology in pGDM
- The outcome of children of mothers with pGDM
- Role of the adipokines in pGDM: i) leptin, ii) adiponectin, iii) resistin, iv) TNF-α, v) other adipokines
- Therapeutic strategies in pGDM: i) agents stimulating certain effect, ii) agents increasing insulin sensitivity, iii) other specific agents, iv) novel therapies, v) for debate, to treat or not to treat?
- Educational programs in pGDM
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ije/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: